Citation Report
List of articles citing

# Bringing the publicsinto health technology assessment and coverage policy decisions: from principles to practice

DOI: 10.1016/j.healthpol.2006.07.009
Health Policy, 2007, 82, 37-50.

**Source:** https://exaly.com/paper-pdf/42043004/citation-report.pdf
**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|---|---|---|---|
| 186 | The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. *Value in Health*, **2008**, 11, 771-83 | 3.3 | 80 |
| 185 | Engaging the public in priority-setting for health technology assessment: findings from a citizens' jury. **2008**, 11, 282-93 | | 86 |
| 184 | Representation and legitimacy in health policy formulation at a national level: perspectives from a study of health technology eligibility procedures in the United Kingdom. *Health Policy*, **2008**, 85, 356-62 | 3.2 | 17 |
| 183 | Public engagement in setting priorities in health care. *Cmaj*, **2008**, 179, 15-8 | 3.5 | 81 |
| 182 | Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening. *International Journal of Technology Assessment in Health Care*, **2008**, 24, 412-22 | 1.8 | 22 |
| 181 | Introducing patient perspective in health technology assessment at the local level. **2009**, 9, 54 | | 28 |
| 180 | New quality and quantity indices in science (NewQIS): the study protocol of an international project. **2009**, 4, 16 | | 71 |
| 179 | A knowledge synthesis of patient and public involvement in clinical practice guidelines: study protocol. **2009**, 4, 30 | | 12 |
| 178 | Health technology assessment in Canada: 20 years strong?. *Value in Health*, **2009**, 12 Suppl 2, S14-9 | 3.3 | 42 |
| 177 | Public involvement in setting a national research agenda: a mixed methods evaluation. *Patient*, **2009**, 2, 179-90 | 3.7 | 32 |
| 176 | Why consider patients' preferences? A discourse analysis of clinical practice guideline developers. **2009**, 47, 908-15 | | 64 |
| 175 | "It all depends": conceptualizing public involvement in the context of health technology assessment agencies. **2010**, 70, 1518-26 | | 85 |
| 174 | The Canadian biotechnology regulatory regime: The role of participation. **2010**, 32, 280-287 | | 2 |
| 173 | User's perspectives of barriers and facilitators to implementing quality colonoscopy services in Canada: a study protocol. **2010**, 5, 85 | | 2 |
| 172 | A Cost Decision Analysis for Diagnosing and Staging. **2010**, 101-110 | | |
| 171 | From actors to authors: a first account about the involvement of patients in the informed consent governance of a major Italian translational research hospital. **2010**, 33, 231-40 | | 3 |
| 170 | Patient and public involvement in clinical practice guidelines: a knowledge synthesis of existing programs. **2011**, 31, E45-74 | | 107 |

| | | | |
|---|---|---|---|
| 169 | Development of a framework for effective community engagement in Ontario, Canada. *Health Policy*, **2011**, 101, 59-69 | 3.2 | 15 |
| 168 | Priority setting for systematic review of health care interventions in Nigeria. *Health Policy*, **2011**, 99, 244-9 | 3.2 | 9 |
| 167 | Health technology assessment in Brazil: what do healthcare system players think about it?. **2011**, 129, 198-205 | | 12 |
| 166 | The integration of citizens into a science/policy network in genetics: governance arrangements and asymmetry in expertise. **2011**, 14, 261-71 | | 23 |
| 165 | Eliciting ethical and social values in health technology assessment: A participatory approach. **2011**, 73, 135-44 | | 60 |
| 164 | Introducing patients' and the public's perspectives to health technology assessment: A systematic review of international experiences. *International Journal of Technology Assessment in Health Care*, **2011**, 27, 31-42 | 1.8 | 106 |
| 163 | Moving cautiously: Public involvement and the health technology assessment community. *International Journal of Technology Assessment in Health Care*, **2011**, 27, 43-9 | 1.8 | 28 |
| 162 | Role of patient and public participation in health technology assessment and coverage decisions. **2011**, 11, 75-89 | | 67 |
| 161 | Stakeholder engagement in comparative effectiveness research: how will we measure success?. **2012**, 1, 397-407 | | 29 |
| 160 | Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. **2012**, 1, 181-194 | | 175 |
| 159 | The changing role of economic evaluation in valuing medical technologies. **2012**, 12, 711-23 | | 14 |
| 158 | An equity framework for health technology assessments. **2012**, 32, 428-41 | | 29 |
| 157 | Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence. **2012**, 30, 4267-74 | | 8 |
| 156 | [Stakeholder participation in priority setting - a consideration of the normative status of quantitative and qualitative methods]. **2012**, 106, 412-7 | | |
| 155 | Stakeholders involvement by HTA Organisations: why is so different?. *Health Policy*, **2012**, 105, 236-45 | 3.2 | 19 |
| 154 | Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes. *BMC Medical Informatics and Decision Making*, **2012**, 12, 83 | 3.6 | 17 |
| 153 | Knowledge mobilization in the context of health technology assessment: an exploratory case study. **2012**, 10, 10 | | 5 |
| 152 | Patient involvement in a scientific advisory process: setting the research agenda for medical products. *Health Policy*, **2012**, 107, 231-42 | 3.2 | 31 |

| | | | |
|---|---|---|---|
| 151 | A systematic review of coverage decision-making on health technologies-evidence from the real world. *Health Policy*, **2012**, 107, 218-30 | 3.2 | 42 |
| 150 | The politics of health technology assessment in Poland. *Health Policy*, **2012**, 108, 178-93 | 3.2 | 20 |
| 149 | What counts and how to count it: physicians' constructions of evidence in a disinvestment context. **2012**, 75, 2191-9 | | 16 |
| 148 | A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines. *Patient*, **2012**, 5, 199-211 | 3.7 | 41 |
| 147 | Involving patients in HTA activities at local level: a study protocol based on the collaboration between researchers and knowledge users. **2012**, 12, 14 | | 15 |
| 146 | Reflections on the evolution of health technology assessment in Europe. *Health Economics, Policy and Law*, **2012**, 7, 25-45 | 2.3 | 30 |
| 145 | An international survey of the public engagement practices of health technology assessment organizations. *Value in Health*, **2013**, 16, 155-63 | 3.3 | 45 |
| 144 | How are European birth-cohort studies engaging and consulting with young cohort members?. **2013**, 13, 56 | | 12 |
| 143 | Assessing the added value of health technologies: reconciling different perspectives. *Value in Health*, **2013**, 16, S7-13 | 3.3 | 50 |
| 142 | Alternatives to seclusion and restraint in psychiatry and in long-term care facilities for the elderly: perspectives of service users and family members. *Patient*, **2013**, 6, 269-80 | 3.7 | 8 |
| 141 | FDA Decisions and Public Deliberation:Challenges and Opportunities. **2013**, 73, S115-S126 | | 15 |
| 140 | Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. *Health Policy*, **2013**, 112, 187-96 | 3.2 | 16 |
| 139 | Ethics in Health Technology Assessment: Understanding Health Technologies as Policies. **2013**, 26, 72-76 | | 5 |
| 138 | Citizens' perspectives on personalized medicine: a qualitative public deliberation study. **2013**, 21, 1197-201 | | 28 |
| 137 | Public engagement in health priority setting in low- and middle-income countries: current trends and considerations for policy. **2013**, 10, e1001495 | | 25 |
| 136 | Link between process and appraisal in coverage decisions: an analysis with structural equation modeling. **2013**, 33, 1009-25 | | 8 |
| 135 | Enhancing citizen engagement in cancer screening through deliberative democracy. **2013**, 105, 380-6 | | 46 |
| 134 | Public engagement in health technology assessment and coverage decisions: a study of experiences in France, Germany, and the United Kingdom. *Journal of Health Politics, Policy and Law*, **2013**, 38, 89-122 | 2.6 | 29 |

| | | | |
|---|---|---|---|
| 133 | Assessing the impacts of citizen deliberations on the health technology process. *International Journal of Technology Assessment in Health Care*, **2013**, 29, 282-9 | 1.8 | 28 |
| 132 | Promotion of health sector reforms for health systems strengthening in Nigeria: perceptions of policy makers versus the general public on the Nigeria health systems performance. **2013**, 28, 541-53 | | 2 |
| 131 | Technological innovation and its effect on public health in the United States. **2013**, 6, 31-40 | | 6 |
| 130 | Emerging Therapeutic Enhancement Enabling Health Technologies and Their Discourses: What Is Discussed within the Health Domain?. **2013**, 1, 20-52 | | 8 |
| 129 | Towards a consumer-informed research agenda for aphasia: preliminary work. **2014**, 36, 1042-50 | | 19 |
| 128 | The use of research evidence on patient preferences in health care decision-making: issues, controversies and moving forward. **2014**, 14, 785-94 | | 22 |
| 127 | Australian Public Preferences for the Funding of New Health Technologies: A Comparison of Discrete Choice and Profile Case Best-Worst Scaling Methods. **2014**, 34, 638-54 | | 35 |
| 126 | Introducing the patient's perspective in hospital health technology assessment (HTA): the views of HTA producers, hospital managers and patients. **2014**, 17, 888-900 | | 23 |
| 125 | Mapping the impact of patient and public involvement on health and social care research: a systematic review. **2014**, 17, 637-50 | | 650 |
| 124 | The use of citizens' juries in health policy decision-making: a systematic review. **2014**, 109, 1-9 | | 133 |
| 123 | Involving patient in the early stages of health technology assessment (HTA): a study protocol. **2014**, 14, 273 | | 12 |
| 122 | 'Practical' resources to support patient and family engagement in healthcare decisions: a scoping review. **2014**, 14, 175 | | 59 |
| 121 | New avenues within community engagement: addressing the ingenuity gap in our approach to health research and future provision of health care. **2014**, 1, 321-328 | | 9 |
| 120 | Barriers and facilitators influencing ethical evaluation in health technology assessment. *International Journal of Technology Assessment in Health Care*, **2015**, 31, 113-23 | 1.8 | 13 |
| 119 | The ideal healthcare: priorities of people with chronic conditions and their carers. **2015**, 15, 551 | | 16 |
| 118 | Conceptualizing the use of public involvement in health policy decision-making. **2015**, 138, 14-21 | | 33 |
| 117 | Preferences for end-of-life care among community-dwelling older adults and patients with advanced cancer: A discrete choice experiment. *Health Policy*, **2015**, 119, 1482-9 | 3.2 | 35 |
| 116 | Health Care Coverage Decision Making in Low- and Middle-Income Countries: Experiences from 25 Coverage Schemes. **2015**, 18, 265-71 | | 7 |

| | | | |
|---|---|---|---|
| 115 | Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey. *Patient*, **2015**, 8, 93-101 | 3.7 | 14 |
| 114 | Which public and why deliberate?--A scoping review of public deliberation in public health and health policy research. **2015**, 131, 114-21 | | 113 |
| 113 | Why orphan drug coverage reimbursement decision-making needs patient and public involvement. *Health Policy*, **2015**, 119, 588-96 | 3.2 | 25 |
| 112 | Participatory health councils and good governance: healthy democracy in Brazil?. *International Journal for Equity in Health*, **2015**, 14, 21 | 4.6 | 11 |
| 111 | Participatory health system priority setting: Evidence from a budget experiment. **2015**, 146, 182-90 | | 5 |
| 110 | Prioritising patients for bariatric surgery: building public preferences from a discrete choice experiment into public policy. **2015**, 5, e008919 | | 10 |
| 109 | Expectations and values about expanded newborn screening: a public engagement study. **2015**, 18, 419-29 | | 18 |
| 108 | Deliberative Processes in Practice. *SSRN Electronic Journal*, **2016**, | 1 | |
| 107 | Addressing Patient Needs and Public Commitments in Health Technology Innovation: A Review of Patient and Public Engagement in Technology Development and Assessment. *SSRN Electronic Journal*, **2016**, | 1 | |
| 106 | The Future of Health Economics. **2016**, | | 1 |
| 105 | Towards a bioethics of innovation. **2016**, 42, 445-9 | | 8 |
| 104 | Developing a decision support system to link health technology assessment (HTA) reports to the health system policies in Iran. *Health Policy and Planning*, **2017**, 32, 504-515 | 3.4 | 3 |
| 103 | PUBLIC AND PATIENT INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT: A FRAMEWORK FOR ACTION. *International Journal of Technology Assessment in Health Care*, **2016**, 32, 256-264 | 1.8 | 67 |
| 102 | Attitudes to incorporating genomic risk assessments into population screening programs: the importance of purpose, context and deliberation. **2016**, 9, 25 | | 7 |
| 101 | Public participation in decision-making on the coverage of new antivirals for hepatitis C. *Journal of Health Organization and Management*, **2016**, 30, 769-85 | 1.9 | 15 |
| 100 | Introduction: priority setting, equitable access and public involvement in health care. *Journal of Health Organization and Management*, **2016**, 30, 736-50 | 1.9 | 25 |
| 99 | Deliberative Processes in Practice. *The International Library of Ethics, Law and Technology*, **2016**, 59-70 | 0.5 | 1 |
| 98 | Big Picture Bioethics: Developing Democratic Policy in Contested Domains. *The International Library of Ethics, Law and Technology*, **2016**, | 0.5 | 1 |

| | | | |
|---|---|---|---|
| 97 | Steps toward improving ethical evaluation in health technology assessment: a proposed framework. *BMC Medical Ethics*, **2016**, 17, 34 | 2.9 | 13 |
| 96 | If you build it, they will come: unintended future uses of organised health data collections. *BMC Medical Ethics*, **2016**, 17, 54 | 2.9 | 33 |
| 95 | Cognitive Enhancement: Social and Public Policy Issues. **2016**, | | 5 |
| 94 | Comparative Effectiveness Research in Health Technology Assessment. **2016**, 57-93 | | 1 |
| 93 | [Involving patients, the insured and the general public in healthcare decision making]. **2016**, 110-111, 36-44 | | 4 |
| 92 | Prioritization in Medicine. **2016**, | | 3 |
| 91 | Public and patient participation in health policy, care and research. **2017**, 2, 31-32 | | 16 |
| 90 | Identifying health system value dimensions: more than health gain?. *Health Economics, Policy and Law*, **2017**, 12, 387-400 | 2.3 | 3 |
| 89 | Public consultation changes guidance on the use of health-care interventions. An observational study. **2017**, 20, 361-368 | | 2 |
| 88 | Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes. *Value in Health*, **2017**, 20, 256-260 | 3.3 | 50 |
| 87 | STAKEHOLDER INVOLVEMENT THROUGHOUT HEALTH TECHNOLOGY ASSESSMENT: AN EXAMPLE FROM PALLIATIVE CARE. *International Journal of Technology Assessment in Health Care*, **2017**, 33, 552-561 | 1.8 | 5 |
| 86 | Public drug policy for children in Canada. *Cmaj*, **2017**, 189, E990-E994 | 3.5 | 4 |
| 85 | Criteria for the prioritization of public health interventions for climate-sensitive vector-borne diseases in Quebec. *PLoS ONE*, **2017**, 12, e0190049 | 3.7 | 5 |
| 84 | OP35 Involving Members Of The Public In A National Screening Programme Health Technology Assessment. *International Journal of Technology Assessment in Health Care*, **2017**, 33, 16-16 | 1.8 | |
| 83 | Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study. *Patient*, **2018**, 11, 353-359 | 3.7 | 4 |
| 82 | Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union. *Value in Health Regional Issues*, **2018**, 16, 81-91 | 1.6 | 10 |
| 81 | Health Technology Assessment. **2018**, 11-22 | | 1 |
| 80 | IMPACT OF HEALTH TECHNOLOGY ASSESSMENT REPORTS ON HOSPITAL DECISION MAKERS - 10-YEAR INSIGHT FROM A HOSPITAL UNIT IN SHERBROOKE, CANADA: IMPACT OF HEALTH TECHNOLOGY ASSESSMENT ON HOSPITAL DECISIONS. *International Journal of Technology Assessment in Health Care*, **2018**, 34, 393-399 | 1.8 | 6 |

| | | | |
|---|---|---|---|
| 79 | The clinical application of gene editing: ethical and social issues. *Personalized Medicine*, **2019**, 16, 337-350 | 2.2 | 15 |
| 78 | Justice and public participation in universal health coverage: when is tiered coverage unfair and who should decide?. *Asian Bioethics Review*, **2019**, 11, 5-19 | 3.4 | 1 |
| 77 | Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. *Value in Health*, **2019**, 22, 1283-1288 | 3.3 | 47 |
| 76 | Towards inclusive priority-setting for global health research projects: recommendations for sharing power with communities. *Health Policy and Planning*, **2019**, 34, 346-357 | 3.4 | 15 |
| 75 | Understanding and using patient experiences as evidence in healthcare priority setting. *Cost Effectiveness and Resource Allocation*, **2019**, 17, 20 | 2.4 | 11 |
| 74 | Involving patients and the public in medical and health care research studies: An exploratory survey on participant recruiting and representativeness from the perspective of study authors. *PLoS ONE*, **2019**, 14, e0204187 | 3.7 | 14 |
| 73 | Citizens' juries can bring public voices on overdiagnosis into policy making. *BMJ, The*, **2019**, 364, l351 | 5.9 | 2 |
| 72 | Methods Assessing Sociocultural Aspects of Health Technologies: Results of a Literature Review. *International Journal of Technology Assessment in Health Care*, **2019**, 35, 99-105 | 1.8 | 1 |
| 71 | Inclusion of Marginalized Groups and Communities in Global Health Research Priority-Setting. *Journal of Empirical Research on Human Research Ethics*, **2019**, 14, 169-181 | 1.6 | 12 |
| 70 | Creating sustainable health care systems. *Journal of Health Organization and Management*, **2019**, 33, 18-34 | 1.9 | 13 |
| 69 | Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. *Value in Health*, **2019**, 22, 13-20 | 3.3 | 45 |
| 68 | Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review. *BMJ, The*, **2019**, 364, k5300 | 5.9 | 25 |
| 67 | The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review. *Value in Health*, **2020**, 23, 3-9 | 3.3 | 6 |
| 66 | Preferences for Primary Healthcare Services Among Older Adults with Chronic Disease: A Discrete Choice Experiment. *Patient Preference and Adherence*, **2020**, 14, 1625-1637 | 2.4 | 1 |
| 65 | [Beyond benefit evaluation: Considering the unintended consequences of telehealth]. *Ethics, Medicine and Public Health*, **2020**, 15, 100596 | 0.7 | 0 |
| 64 | Developing a toolkit for engagement practice: sharing power with communities in priority-setting for global health research projects. *BMC Medical Ethics*, **2020**, 21, 21 | 2.9 | 7 |
| 63 | Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes. *International Journal of Technology Assessment in Health Care*, **2020**, 36, 87-95 | 1.8 | 8 |
| 62 | Rethinking the electronic health record through the quadruple aim: time to align its value with the health system. *BMC Medical Informatics and Decision Making*, **2020**, 20, 32 | 3.6 | 10 |

| | | | |
|---|---|---|---|
| 61 | (Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time. *Health Economics, Policy and Law*, **2021**, 16, 424-439 | 2.3 | 3 |
| 60 | What are Important Ways of Sharing Power in Health Research Priority Setting? Perspectives From People With Lived Experience and Members of the Public. *Journal of Empirical Research on Human Research Ethics*, **2021**, 16, 200-211 | 1.6 | |
| 59 | Sharing power in global health research: an ethical toolkit for designing priority-setting processes that meaningfully include communities. *International Journal for Equity in Health*, **2021**, 20, 127 | 4.6 | 2 |
| 58 | Health Technology Assessment Development in Vietnam: A Qualitative Study of Current Progress, Barriers, Facilitators, and Future Strategies. *International Journal of Environmental Research and Public Health*, **2021**, 18, | 4.6 | 0 |
| 57 | Implications of the Health Equity Perspective for the Right to Health. **2021**, 337-363 | | |
| 56 | What the UN Human Rights Treaty Bodies Tell Us about Economic Inequalities and Human Rights: An Empirical Analysis of Twenty Years of Practice. **2021**, 85-114 | | |
| 55 | Index. **2021**, 390-418 | | |
| 54 | Distributive Justice, and Economic and Social Rights. **2021**, 247-270 | | |
| 53 | Economic Inequality and the Right to Social Security: Contested Meanings and Potential Roles. **2021**, 295-315 | | |
| 52 | Human Rights and Economic Inequalities. **2021**, | | 0 |
| 51 | A Framework for Fiscal Justice: How Human Rights Can Change Public Finance. **2021**, 143-167 | | |
| 50 | How Can Economists Help Human Rights Practitioners to Measure Changes in Economic Inequalities?. **2021**, 115-140 | | |
| 49 | Constraints on Economic Inequality: Comparing Canada and the United States. **2021**, 63-84 | | |
| 48 | Global Tax Justice and Human Rights. **2021**, 168-192 | | |
| 47 | Education, Income Inequality and the Right to Participate in Cultural Life. **2021**, 316-336 | | |
| 46 | Fair Wages and a Decent Living: Paths to Greater Vertical Equality. **2021**, 271-294 | | |
| 45 | Growing Inequality and Risks to Social Rights in Our New Data Economy. **2021**, 193-216 | | |
| 44 | Caste, Economic Inequality, and Climate Justice in India. **2021**, 217-244 | | |

| | | | |
|---|---|---|---|
| 43 | Introduction. **2021**, 1-30 | | |
| 42 | Emerging Human Rights Norms and Standards on Vertical Inequalities. **2021**, 33-62 | | |
| 41 | The Potential Impact of the Right to Housing to Address Vertical Inequalities. **2021**, 364-389 | | |
| 40 | Achieving inclusive research priority-setting: what do people with lived experience and the public think is essential?. *BMC Medical Ethics*, **2021**, 22, 117 | 2.9 | 3 |
| 39 | Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada. *Technological Forecasting and Social Change*, **2021**, 171, 120960 | 9.5 | 0 |
| 38 | Patient and public involvement in health technology assessment: update of a systematic review of international experiences. *International Journal of Technology Assessment in Health Care*, **2021**, 37, e36 | 1.8 | 3 |
| 37 | Comparative Effectiveness Research in Health Technology Assessment. **2015**, 1-38 | | 2 |
| 36 | Involving Patients in Hospital-Based HTA: Experiences, Approaches, and Future Directions. **2016**, 345-359 | | 1 |
| 35 | Evaluation of Patient Involvement in HTA. **2017**, 201-213 | | 6 |
| 34 | Discussion: Research to Promote Patient-Based HTA. **2017**, 225-233 | | 1 |
| 33 | Reflections on Terms, Goals and Organisation. **2017**, 31-42 | | 1 |
| 32 | Just Access? Questions of Equity in Access and Funding for Assistive Technology. *Ethics and Behavior*, **2019**, 29, 172-191 | 1.4 | 16 |
| 31 | "Getting to the Table": Changing Ideas about Public and Patient Involvement in Canadian Drug Assessment. *Journal of Health Politics, Policy and Law*, **2019**, 44, 631-663 | 2.6 | 9 |
| 30 | Harnessing the potential to quantify public preferences for healthcare priorities through citizens' juries. *International Journal of Health Policy and Management*, **2014**, 3, 57-62 | 2.5 | 19 |
| 29 | Collaboration Between Researchers and Knowledge Users in Health Technology Assessment: A Qualitative Exploratory Study. *International Journal of Health Policy and Management*, **2017**, 6, 437-446 | 2.5 | 4 |
| 28 | Stakeholder Participation for Legitimate Priority Setting: A Checklist. *International Journal of Health Policy and Management*, **2018**, 7, 973-976 | 2.5 | 11 |
| 27 | A Pilot Study to Identify Areas for Further Improvements in Patient and Public Involvement in Health Technology Assessments for Medicines. *Patient*, **2012**, 5, 199-211 | 3.7 | 13 |
| 26 | Involving Citizen-Patients in the Development of Telehealth Services: Qualitative Study of Experts' and Citizen-Patients' Perspectives. *Journal of Participatory Medicine*, **2018**, 10, e10665 | 1.4 | 7 |

| | | | |
|---|---|---|---|
| 25 | [Organizational and systemic conditions of citizen-patient involvement in ́the development of telehealth in Quebec]. *Sante Publique*, **2019**, Vol. 31, 125-135 | | 0 |
| 24 | Means of Knowledge Dissemination: Are the <i>Café Scientifique</i> and the Artistic Performance Equally Effective?. *Sociology Mind*, **2012**, 02, 191-199 | 0.1 | 8 |
| 23 | Legal Governance in HTA: Environment, Health and Safety Issues´/ Ethical, Legal and Social Issues´(EHSI/ELSI), the Ongoing Debate. *Canadian Journal of Bioethics*, **2020**, 3, 83 | 0.5 | 2 |
| 22 | Pitfalls in reimbursement decisions for oncology drugs in South Korea: need for addressing the ethical dimensions in technology assessment. *Asian Pacific Journal of Cancer Prevention*, **2013**, 14, 3785-92 | 1.7 | 3 |
| 21 | Where Public Health Meets Ethics. Conceptual Foundations and Practical Challenges of Public Health. *Public Health Ethics Analysis*, **2013**, 5-23 | 0.2 | |
| 20 | Impacts of Public Participation on Public Budgeting Process of Kurdistan. *SSRN Electronic Journal*, | 1 | 0 |
| 19 | Fair Innings as a Basis for Prioritization: An Empirical Perspective. **2016**, 179-196 | | |
| 18 | Seeking Community Views on Allocation of Scarce Resources in a Pandemic in Australia: Two Methods, Two Answers. *The International Library of Ethics, Law and Technology*, **2016**, 245-261 | 0.5 | |
| 17 | Involving patients and publics in medical and health care research studies: an exploratory survey on participant recruiting and representativeness from the perspective of study authors. | | 1 |
| 16 | Troutville: Where People Discuss Fairness Issues. *Canadian Journal of Bioethics*, **2020**, 3, 70 | 0.5 | 0 |
| 15 | How good is good enough? Standards in policy decisions to cover new health technologies. *Healthcare Policy*, **2007**, 3, 91-101 | 1.1 | 14 |
| 14 | Patient advocacy group involvement in health technology assessments: an observational study. *Research Involvement and Engagement*, **2021**, 7, 83 | 4.4 | 0 |
| 13 | Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?. *Frontiers in Medical Technology*, **2022**, 4, 810315 | 1.9 | 0 |
| 12 | Overcoming structural barriers to sharing power with communities in global health research priority-setting: Lessons from the Participation for Local Action project in Karnataka, India.. *Global Public Health*, **2022**, 1-19 | 3.5 | 1 |
| 11 | Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.. *Iranian Journal of Pharmaceutical Research*, **2021**, 20, 92-106 | 1.1 | |
| 10 | Mechanisms to Bridge the Gap Between Science and Politics in Evidence-Informed Policymaking: Mapping the Landscape. **2022**, 293-328 | | 1 |
| 9 | Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries. *Frontiers in Public Health*, 10, | 6 | |
| 8 | Public preferences regarding the priority setting criteria of health interventions for budget allocation: results of a survey of Iranian adults. **2022**, 22, | | 0 |

| | | |
|---|---|---|
| 7 | Public Engagement through Inclusive Deliberation: The Human Genome International Commission and Citizens Juries. 1-11 | 0 |
| 6 | Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions. | 0 |
| 5 | Participaci n en salud em las Am ricas: mapeo bibliom trico de producci n, impacto, isibilidade y colaboraci n. **2023**, 28, 487-500 | 0 |
| 4 | Participa o em sa de nas Am ricas: mapeamento bibliom trico da produ o, impacto, visibilidade e colabora o. **2023**, 28, 487-500 | 0 |
| 3 | Participation in health in the Americas: Bibliometric mapping of production, impact, visibility and collaboration. **2023**, 28, 487-500 | 0 |
| 2 | Towards conceptualizing patients as partners in health systems: a systematic review and descriptive synthesis. **2023**, 21, | 0 |
| 1 | Governance and Public Participation. **2023**, 29-45 | 0 |